Investor’s Business Daily |
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In …
Investor’s Business Daily AnaptysBio (ANAB) launched to a record high Tuesday after its eczema drug appeared to outperform Regeneron Pharmaceuticals' (REGN) and Sanofi's (SNY) … Here's Why AnaptysBio Inc. Is Rocketing Higher Today AnaptysBio Reports Positive Phase 2a Clinical Trial for Dermatitis drug AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis |